

# Spotlight on single-cell transcriptomics

Uncover deeper insights into  
complex cellular biology at  
single-cell resolution



## Introduction

The transcriptome reveals key information about the functional elements of the genome under various conditions. Next-generation sequencing (NGS) technology has revolutionized the field of transcriptomics by enabling thousands of genes to be profiled simultaneously on a genome-wide scale, offering broad insights into gene expression in health and disease. NGS-based RNA sequencing (RNA-Seq) can quantify the number of transcripts for each gene, providing an unbiased snapshot of actively expressed genes under dynamic conditions. The flexibility and accuracy of RNA-Seq allows researchers to uncover novel features, such as transcript isoforms, gene fusions, and single nucleotide variants, in a strand-specific manner without the limitations of prior knowledge.<sup>1,2</sup>

The conventional approach to transcriptomics involves bulk analysis of gene expression averaged across thousands of cells in a sample. Though bulk RNA-Seq has been successfully applied to understand differential gene expression at a population scale, it does not quantify the inherent heterogeneity of cells within tissues. Transcripts can be expressed at different levels within a cell population, either due to environmental signals or stochastic changes that occur over time. Gene expression also varies substantially based on tissue of origin. In addition, bulk RNA-Seq may potentially fail to capture transcripts from rare but biologically relevant subpopulations, such as stem cells or circulating tumor cells (CTCs). A low-expressing gene identified in bulk RNA-Seq may instead be robustly expressed in a rare cell type. Obtaining data from single cells overcomes these limitations, enabling researchers to gain a clearer understanding of cellular function at single-cell resolution (Figure 1).

Over the past decade, the field of single-cell transcriptomics, or single-cell RNA-Seq (scRNA-Seq), has undergone exponential growth, enabling unprecedented insights into cellular function and how subpopulations of cells interact with their microenvironments.<sup>3</sup> Early single cell gene expression approaches involved manual methods for cell isolation, such as micropipetting, to characterize individual cells. Today, several higher throughput methods are available to capture single cells. Regardless of the single-cell isolation method used, Illumina NGS technology maximizes the discovery power of single-cell gene expression studies, enabling researchers to assay millions




Figure 1: Comparison between bulk and single-cell RNA-Seq approaches—With bulk analysis (top), gene expression is averaged across all the cells included in the sample. However, with scRNA-Seq gene expression (bottom) data are generated for individual cells, enabling deeper insights into the nuanced distinctions between cells within the same sample.

of individual cells in a single assay with high accuracy and sensitivity. Illumina sequencing platforms, including the NextSeq™ 500, NextSeq 550, NextSeq 1000, NextSeq 2000, NovaSeq™ 6000, and NovaSeq X systems, deliver exceptional data quality and accuracy across a wide range of throughputs. Integration with the DRAGEN™ Bio-IT Platform single-cell analysis pipeline, and compatibility with third-party single-cell platforms, provides a streamlined solution to analyze the vast amounts of data generated by scRNA-Seq experiments. Flexible NGS readouts can be used to analyze genomes, transcriptomes, epigenomes, and proteomes, making it well suited for large-scale multiomics applications.

This application note highlights the latest advancements and emerging trends in the rapidly evolving field of single-cell transcriptomics. Also presented is a brief overview of the expanding portfolio of scRNA-Seq methods and technology solutions from Illumina available to support single-cell research goals.

## Applications of scRNA-Seq

scRNA-Seq has demonstrated utility in various applications, ranging from basic to translational and clinical research. This powerful approach has been applied to several disciplines, including developmental biology, neurobiology, immunology, and cancer biology, enabling researchers to make significant strides in understanding complex biological systems (Figure 2). scRNA-Seq methods can also be used to investigate differential gene expression and cellular heterogeneity in time-dependent processes, such as differentiation, proliferation, and tumorigenesis.

### Cell atlasing

A complete molecular cell atlas of human and model organism tissues is an essential first step for assessing cellular changes due to disease states, aging, or response to treatments. However, mammalian tissues are highly complex structures, composed of diverse cell types with varying abundances, making it challenging to capture the full scope of cellular heterogeneity using bulk RNA-Seq alone. Single-cell approaches have been instrumental in enabling researchers to build detailed cellular maps of tissues, transforming our understanding of biology and disease.<sup>3,4</sup> For instance, single-cell transcriptomics analysis with antibody-based protein profiling was recently used to create a single-cell type transcriptomics map of 13 human tissues, which included data for all protein-coding genes.<sup>4</sup> Building on this progress, the Human Cell Atlas (HCA) Project is using high-throughput scRNA-Seq data to create a comprehensive map of all cell types across complex tissues to reveal vital information about cellular functions and regulation, from individual cells up to tissues and organ systems, building a solid foundation for future biological research.<sup>5</sup>

### Immunology

The immune system is highly complex, consisting of multiple cell types with the potential to alter their gene expression profiles based on environmental cues. Flow cytometry and fluorescence-assisted cell sorting (FACS) have been the mainstays of immunophenotyping studies. However, these single-approaches are low throughput and limited by the need for suitable antibodies for isolating cell populations of interest.



Figure 2: Applications of scRNA-Seq—Single-cell approaches have a broad range of applications across diverse research areas.

Advances in scRNA-Seq methodologies are powering large, unbiased investigations into immune cell phenotypes. As a result, researchers can now access new insights into immune cell development, activation-induced responses, rare immune cell subpopulations, and responses to vaccination or infections (Figure 3).

### Immune repertoire profiling

A defining feature of the adaptive immune response is the ability of immune receptors to generate a rapid immune response against a wide range of pathogens. T- and B-cell receptors (TCR and BCR, respectively) undergo random recombination of variable (V), diversity (D), and joining (J) gene segments to produce a highly diverse antibody repertoire. BCRs also undergo somatic hypermutations to further refine antigen-binding affinity. scRNA-Seq provides a unique opportunity to investigate this extreme immunoreceptor diversity with high accuracy and resolution. Correctly identifying T-cell clonality, for example, may reveal T-cell subset-specific TCR diversity that may be associated with pathogenicity.<sup>6,7</sup> One of the challenges of immune repertoire sequencing using heterogenous bulk samples is determining which  $\alpha$  and  $\beta$  chains combine to form the functional TCR or BCR unit. Unlike bulk RNA-Seq, scRNA-Seq enables pairing of both  $\alpha$  and  $\beta$  chains of TCR and BCRs, revealing a more holistic view of their antigen specificity.





Figure 3: Applications of scRNA-Seq in immunology—The immune system consists of highly specialized cell types that work in concert to protect the host from invading pathogens, cancer cells, and self-directed antigens. Using scRNA-Seq and multiomics approaches, researchers can deconvolute the complex biology of the immune system at single-cell resolution.

TCR antigen-specificity profiling by scRNA-Seq provides key information about T-cell functionality, cellular phenotype, receptor sequence, and peptide-major histocompatibility complex (MHC).<sup>8</sup> This approach has also been applied to identify tumor-specific T-cells that can then be used for adoptive cell immunotherapy<sup>9</sup> or determine response to chimeric antigen receptor (CAR) T-cell therapy.<sup>10</sup>

#### Immune response to infection and vaccination

Delineating the changes in BCR repertoire in response to infection offers important information to aid in biomarker discovery and development of novel therapeutics. BCR-Seq and scRNA-Seq have been applied to characterize the TCR<sup>11</sup> and BCR<sup>12</sup> immune repertoire profiles in response to *Pneumocystis* infection, a life-threatening complication of immunosuppression. LIBRA-Seq (linking BCR to antigen specificity through sequencing) is a single-cell technique being increasingly used to assess BCR repertoire changes due to infection or vaccination.<sup>13</sup> This approach has been used to identify key changes in clonal proliferation and BCR repertoire dynamics in the lungs, draining lymph nodes, and the spleen after influenza infection.<sup>14</sup> Similarly, LIBRA-Seq has been used to create a comprehensive profile of the memory B cell transcriptomic signatures in response to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).<sup>15</sup> In addition, LIBRA-Seq has identified multiple SARS-CoV-neutralizing antibodies that can be further investigated as potential therapeutics for coronavirus disease 2019 (COVID-19).<sup>16</sup>

 For more information on immune receptor profiling, read the [Multiomic interrogation of the immune system at single-cell resolution](#) application note

#### Autoimmunity

Autoimmune disorders are challenging to study owing to the heterogeneity of disease phenotypes and variable responses to therapies. Molecular mechanisms underlying autoimmunity are also not well understood, further complicating diagnosis and treatment. A combination of scRNA-Seq and single-cell epigenomics was used to characterize diverse immune subsets in germinal centers (GCs).<sup>17</sup> This study revealed that the expression of key immune-regulatory genes was dysregulated in GCs, implicating aberrant GC-reactions in autoimmune disease pathogenesis.<sup>17</sup> Transcription profiles of key cell populations involved in ulcerative colitis have been characterized using scRNA-Seq to create a comprehensive single-cell atlas of the healthy and diseased colon.<sup>18</sup> Recently, multiplexed scRNA-Seq has been applied to characterize circulating immune cell populations and identify transcriptional signatures in systemic lupus erythematosus (SLE).<sup>19</sup>

#### Neurobiology

Single-cell approaches have the potential to address diverse areas of basic and translational neuroscience to understand brain physiology and pathology. However, isolation of single cells from samples, such as frozen human brain tissue, is challenging. Single-nucleus RNA-Seq (snRNA-Seq) is an alternative to scRNA-Seq that enables transcriptomic profiling at single-cell resolution.<sup>20</sup> Researchers at the Allen Institute of Brain Science are using snRNA-Seq data to develop a comprehensive brain atlas with transcriptional profiles for key brain regions, including the cortex, hippocampus, and thalamus.<sup>21</sup> Similar approaches have been used to create a single-

cell atlas of the developing human brain.<sup>22</sup> Single-nucleus chromatin accessibility and transcriptomic profiling has been applied to uncover disease-specific transcription factors and their regulatory targets in Alzheimer's disease.<sup>23</sup> Analysis of circulating cells in cerebrospinal fluid by scRNA-Seq has emerged as a promising approach to studying neurological diseases, including Alzheimer's disease,<sup>24</sup> multiple sclerosis,<sup>24,25</sup> and neurological sequelae of COVID-19.<sup>27</sup> Recently, a single-cell approach known as CITE-Seq (single-cell cellular indexing of transcriptomes and epitopes by sequencing) was used to characterize epileptic lesions.<sup>28</sup> Extensive microglial activation and proinflammatory immune cell infiltration in these lesions may inform future therapeutic development for drug-resistant epilepsy.<sup>28</sup>

## Stem cell and developmental biology

Rapid developments in the area of scRNA-Seq have facilitated deeper insights into embryogenesis and stem cell biology.<sup>29</sup> Induced pluripotent cells (iPSCs) have a relatively low rate of successful transformation<sup>30</sup> and understanding the underlying factors that drive this heterogeneity is critical to achieving the promise of regenerative medicine. scRNA-Seq has been used to assess endoderm differentiation across multiple human iPSCs.<sup>31</sup> This study characterized common genetic variants and their influence on defined time points during early differentiation, providing critical information about the causal role for genetic variation in developmental disorders. scRNA-Seq has also been applied to characterize transcriptional heterogeneity in mesenchymal stem cells<sup>32</sup> and limbal stem cells.<sup>33</sup> Using scRNA-Seq, researchers have uncovered a rare subpopulation of adult neural stem cells that undergo activation in response to brain injury and may play a role in tissue

repair.<sup>34</sup> Cancer stem cell (CSC) profiling is another area of active investigation using scRNA-Seq. CSCs are rare subpopulations within tumors that are frequently resistant to conventional treatments and play a key role in promoting metastasis and recurrence. scRNA-Seq has been applied to characterize CSCs in several recurrent cancers,<sup>35-38</sup> revealing potential targets for therapy.

## Cancer research


Single-cell methods have transformed the landscape of cancer research by uncovering crucial information about intratumoral heterogeneity and the tumor microenvironment (Figure 4). Tumors are known to be highly heterogeneous, comprised of multiple clones of cancer cells interacting with cells in their microenvironment. Though bulk RNA-Seq approaches have been used extensively to identify gene expression signatures for multiple tumor types,<sup>39-41</sup> these findings are not uniformly reproducible due to the high degree of complexity that exists within and between tumors. Solid tumors also contain various infiltrating immune and stromal cells, each with their own transcriptional programs that can affect tumor progression, metastasis, and treatment response. scRNA-Seq can also be leveraged to discover novel therapeutic targets and identify drug candidates that can be advanced to clinical trials.<sup>42</sup>

### Tumor heterogeneity

Single-cell transcriptomics has emerged as a powerful method for investigating transcriptome heterogeneity, identifying rare biologically important clones, characterizing which molecular pathways they utilize, and predicting therapy response in cancer research (Figure 5). scRNA-Seq was applied to dissect divergent tumor



Figure 4: Applications of scRNA-Seq in cancer research—scRNA-Seq has powered breakthrough discoveries in understanding tumor evolution and heterogeneity, monitoring disease progression and metastasis, predicting response to immunotherapies, and overcoming chemoresistance.



**Figure 5: Tumor heterogeneity uncovered by scRNA-Seq**—Single-cell transcriptomics studies can be leveraged to characterize rare cancer cell subpopulations, circulating tumor cells, and tumor infiltrating immune cells at high resolution.

composition and regulators of stemness in primary glioblastoma<sup>43</sup> and oligodendroma.<sup>44</sup> A similar approach was used to investigate intratumor diversification in colorectal cancer (CRC), revealing that CRC clones contain substantial levels of somatic mutations that can influence their response to anticancer agents.<sup>45</sup> Bulk RNA-Seq data were further refined using scRNA-Seq to re-define lung cancer<sup>46</sup> and head and neck cancer<sup>47</sup> subtypes, and predict their tendency to metastasize.

### Immunotherapy response

Immune cell infiltration is commonly observed in multiple tumors. The biological characteristics of these immune cells can have a significant impact on tumor progression and can predict the success of immunotherapy. Characterization of the divergent transcriptional profiles of these immune cell populations is now possible as a result of scRNA-Seq.<sup>48</sup> For instance, scRNA-Seq has been applied to categorize tumor-infiltrating myeloid cells into over 25 different states based on their gene expression signatures.<sup>49</sup> Using scRNA-Seq researchers have identified that a high proportion of infiltrating CD8<sup>+</sup> T lymphocytes is associated with better outcomes in nonsmall cell lung cancer.<sup>50</sup> Similarly, a rare subpopulation of CD8<sup>+</sup> T lymphocytes has been linked to a favorable response to adoptive cell transfer immunotherapy in melanoma.<sup>51</sup> Conversely, scRNA-Seq has identified that higher regulatory T-cell infiltration is associated with poorer prognosis in liver cancer.<sup>51</sup> Single-cell approaches have also been used to determine checkpoint inhibitor

immunotherapy response in sarcoma<sup>53</sup> and metastatic melanoma.<sup>54-56</sup>

### Treatment selection

Data from scRNA-Seq can detect rare treatment-resistant cell populations within heterogeneous tumors, which can aid in selection of appropriate therapeutic approaches. For example, small populations of metastatic melanoma cells expressing high levels of AXL have been identified by scRNA-Seq.<sup>57</sup> This treatment-resistant subpopulation of cells can be predicted to undergo clonal selection in response to conventional treatment with RAF or MEK inhibitors. Instead, tumors with the AXLhi transcriptional signature would be more likely respond to treatment with AXL inhibitors.<sup>58</sup> Similarly, scRNA-Seq data has been used to create prediction models to determine drug responses in breast cancer cell lines.<sup>59</sup>

### Tumor microenvironment


Most solid tumors contain cancer-associated fibroblasts (CAFs) that can participate in tumorigenesis and metastasis. Though these cells are known to play a key role in establishing and maintaining the tumor microenvironment,<sup>60</sup> the mechanisms by which they do so is under active investigation. The lack of reliable biomarkers for CAFs makes it challenging to study these cells using conventional methods. Researchers have successfully leveraged scRNA-Seq to identify multiple populations of CAFs, including their cellular origins, in breast<sup>61,62</sup> and colorectal<sup>63</sup> tumors. This critical information has paved the way for future research into CAFs as potential therapeutic targets.<sup>42</sup>

### Circulating tumor cells (CTCs)

An emerging application of scRNA-Seq is the characterization of CTCs for noninvasive liquid biopsy to detect early or recurrent disease. Tumor-derived CTCs are highly heterogeneous. Single-cell transcriptomics is a promising approach to characterize CTCs accurately, enabling researchers to predict cancer progression and response to treatment. scRNA-Seq has been applied for CTC analysis in multiple cancer types, including breast,<sup>64-67</sup> liver,<sup>68</sup> prostate,<sup>69,70</sup> and gastric<sup>71</sup> cancers.

## scRNA-Seq workflow

The scRNA-workflow consists of four key steps, tissue preparation, single cell isolation and library preparation, sequencing, and data analysis (Figure 6). Illumina offers a growing portfolio of sequencing and data analysis solutions that integrate with commercially available single-cell platforms to support various scRNA-Seq research needs.

 For detailed methods, see the [Illumina single-cell methods guide](#)

### Tissue preparation

A successful scRNA-Seq experiment begins with a high-quality monodispersed suspension of live cells. Tissues of interest are dissociated with mechanical or enzymatic means, or a combination of these methods, to break down the extracellular matrix and obtain a suspension of viable cells for further processing. This step can be followed by protocols to enrich or eliminate specific cell populations, including gradient centrifugation, flow cytometry, or magnetic bead-based enrichment methods. Optimized enrichment and quality control (QC) steps are essential to ensure a high yield of viable cells for scRNA-Seq.

### Single-cell isolation

The single-cell isolation method used in transcriptomics studies has a significant impact on the overall scRNA-Seq results. Several high- and low-throughput methods are available to isolate single cells from cell suspensions for library preparation and sequencing.

Frequently used single-cell isolation methods include:

- **Flow sorting:** Microdroplets containing single cells are isolated using an electric charge. This method selects cell types accurately based on size, morphology, internal complexity, and protein expression by antibody labeling.
- **Droplet fluidics platform:** This approach uses compartmentalization of individual cells in droplets using a microfluidics device followed by lysis and capture of target DNA and RNA.<sup>72-74</sup> The ability to use unique molecular identifiers (UMIs) and cell barcodes enables cell and gene-specific identification.
- **Microwells:** Microwells containing fabricated arrays are used to capture individual cells.<sup>75,76</sup> This method is ideal for adherent cells and is also compatible with UMIs and cell barcoding.
- **Combinatorial indexing or plate-based methods:** Intact cells or nuclei are tagged via multiple rounds of splitting, pooling, and ligation to generate different barcode combinations, enabling thousands of cells to be profiled simultaneously.<sup>77,78</sup>

### Library preparation

Single-cell isolation is followed by library preparation. A range of library preparation methods are available to generate barcoded single-cell gene expression libraries ready for sequencing on Illumina systems (Table 1). Prepared libraries are assessed for quality and quantity before proceeding to sequencing. Researchers can use lower throughput Illumina sequencing systems, including the iSeq™ 100 System, for library QC and rebalancing of pooled samples.




Figure 6: Single-cell sequencing workflow—The scRNA-Seq workflow begins with initial tissue dissociation, followed by isolation of single cells, library preparation, sequencing, and finally, data analysis and visualization. FACS, fluorescence-assisted cell sorting.


Table 1: Library preparation methods for scRNA-Seq applications

Method	Description	Sequencing depth
Full-length RNA-Seq	Switching mechanism at 5' end of template (SMART) technology enables amplification of full-length cDNA	10–20K read pairs/cell
mRNA end-tag amplification (3' WTA or 5' WTA)	Capture of mRNA by 3' polyadenylated (poly-A) tails enables sequencing of the coding transcriptome with strand-specific information	15–50K read pairs/cell
Targeted panels	Pre-designed single-cell targeted RNA sequencing panels enable T-cell, breast cancer profiling, and more	200 reads/amplicon/cell
Immune repertoire sequencing (IR-Seq)	Targeted sequencing method used to quantify the composition of BCR or TCR repertoires	5K reads/cell

WTA, whole-transcriptome amplification; BCR, B-cell receptor; TCR, T-cell receptor.

## Sequencing

Prepared single-cell libraries are sequenced on Illumina sequencing systems to generate highly accurate and reliable sequencing data across a range of throughputs. Illumina NextSeq 550, NextSeq 1000, and NextSeq 2000 systems are suitable for mid- to high-throughput single-cell studies. NovaSeq 6000 and NovaSeq X systems are powerful, scalable Illumina platforms, ideal for high-throughput applications. All Illumina sequencing systems provide a single NGS readout that can be applied across a range of single-cell applications, including scRNA-Seq, spatial RNA-Seq, assay for transposase-accessible chromatin using sequencing (ATAC-Seq), immunoreceptor sequencing (IR-Seq), CITE-Seq, and a host of emerging applications.

 For a detailed scRNA-Seq protocol using 10x Genomics Chromium Single-Cell Gene Expression on Illumina platforms, read the [Explore the transcriptome at single-cell resolution](#) technical note

## Data analysis


The analysis pipeline for single-cell experiments consists of three phases: primary analysis or base calling, secondary analysis, and tertiary analysis and data visualization.

- **Base calling:** Illumina sequencing systems generate raw data files in the binary base call (BCL) format. Illumina BCL Convert standalone app or CellRanger software from 10x Genomics can be used to convert BCL outputs

to FASTQ format, which can then be used as input for a wide range of secondary data analysis tools.

- **Secondary analysis:** Following primary analysis, scRNA-Seq data can be transferred, stored, and analyzed securely in Illumina [BaseSpace Sequence Hub](#), a cloud-based environment for data analysis. Software packages, such as the DRAGEN Single-Cell App, can be used for alignment, variant calling, and data QC. The 10x Genomics CellRanger software also contains multiple secondary analysis pipelines for scRNA-Seq data.
- **Tertiary analysis and data visualization:** This step involves data interpretation and visualization to gain novel insights into cellular function at single-cell resolution. Popular tertiary analysis tools for single-cell data include Seurat, Scanpy, AnnData, 10x Genomics Loupe Cell Browser, and MissionBio Tapestry Insights. SeqGeq is a desktop application cell developed by BD Biosciences, offering direct integration with BaseSpace Sequence Hub for simplified clustering analysis and visualization of single-cell data. Cell by gene expression matrix outputs generated by the DRAGEN Single-Cell App are compatible with all these tertiary analysis software tools.

 For information on the DRAGEN Single-Cell App, read the [DRAGEN v3.7: Single-cell RNA, PrecisionFDA accuracy gains, and more](#) blog article


 Sample scRNA-Seq data sets and test runs on Illumina sequencing systems are available on [BaseSpace Sequence Hub data page](#)





## Emerging trends in single-cell transcriptomics research

### Multiomics

Multiomics combines insights gleaned through multiple ‘omics’ approaches, such as genomics, transcriptomics, epigenomics, and proteomics, providing a high-dimensional view of cellular processes (Figure 7). CITE-Seq is a multiomics approach that uses oligonucleotide-labeled antibodies to convert protein detection into a quantitative assay by NGS.<sup>79</sup> By linking single-cell transcriptomics to cellular protein expression, CITE-Seq provides a novel approach to cellular phenotyping. A newer application of CITE-Seq, known as expanded CRISPR-compatible cellular indexing of transcriptomes and epitopes by sequencing (ECCITE-Seq or Perturb-Seq), is a powerful multiomics approach to interrogate single-cell transcriptomics and cell surface protein markers in CRISPR screens.<sup>80</sup> Perturb-Seq provides crucial insights into the phenotype and clonotype of immune cells, along with their gene expression signatures. Single-cell ATAC-Seq and Gene Expression (ATAC-Seq + GE)<sup>81</sup> is another multiomics tool enabling simultaneous detection of gene expression and chromatin accessibility from the same cell. Multiomic profiling of the transcriptome and epigenome at single-cell resolution enables deeper insights into gene regulatory networks and cellular heterogeneity in health and disease.<sup>82</sup>

 For more information on multiomics, read the [Illumina multiomics e-book](#)

 For details on CITE-Seq using BioLegend TotalSeq antibodies, read the [Correlated expression of protein and RNA reveals a unique molecular signature in Th1 polarized cells](#) application note

 For details on single-cell ATAC-Seq + GE, read the [Unify single-cell gene expression and chromatin accessibility](#) technical note

### Spatial analysis

The native tissue microenvironment has a significant impact on gene expression. While single-cell transcriptomics data provides valuable data about cellular phenotypes and functional characteristics, the isolation of individual cells results in the loss of critical context







Figure 7: Multiomics in single-cell research—Multiple layers of information provide novel insights into complex biological systems that cannot be resolved by scRNA-Seq studies alone.

regarding cellular localization. Spatial transcriptomics enables researchers to uncover cellular networks within tissues, gain a deeper understanding of cell-to-cell communication.<sup>83</sup> Spatially resolved scRNA-Seq has been applied to characterize tissue architecture and cellular dynamics in the bone marrow<sup>84</sup> as well as breast,<sup>85</sup> colorectal,<sup>86</sup> and pancreatic<sup>42,87</sup> cancers.

 For an overview of spatially-resolved transcriptomics using the NanoString GeoMx<sup>®</sup> Digital Spatial Profiler with Illumina NGS readout, read the [High-resolution, high-throughput spatial transcriptomics of complex tissues](#) application note

 For more information on spatial proteogenomics, read the [High-plex spatial proteogenomics of FFPE tissue sections](#) application note

 For a detailed protocol to map the spatially-resolved transcriptome from tissue sections with 10x Genomics Visium Spatial Gene Expression, read the [Resolve the whole transcriptome within tissue architecture](#) technical note

### Temporal analysis

Current scRNA-Seq methods capture static gene expression to characterize cellular phenotype and function. However, the process of gene expression in tissues is inherently dynamic. Innovations in library preparation methods enabling fixation of single cells combined with increased affordability of scRNA-Seq have paved the way for time-course sampling in single-cell analyses. Single-cell RNA velocity (scVelo) is a useful

indicator of transcriptional dynamics in cell populations.<sup>88</sup> RNA velocity measures the ratio of unspliced to spliced reads, which can be used to infer temporal changes in gene expression, even from a sample taken at a single time point. This is an area of active investigation, with computational and modeling methods being developed to resolve the temporal characterization of gene expression in single cells.<sup>89</sup>

## Sample multiplexing

As single-cell transcriptomics research continues to progress, there is a growing need for cost-effective approaches to run more samples per experiment. One method of sample multiplexing, known as MULTI-Seq, uses lipid-tagged indexes to barcode samples.<sup>90</sup> Another approach uses sample-specific genetic polymorphisms as fingerprints to identify individual cells in a pooled sample.<sup>91</sup> Cell hashing is a multiplexing approach that builds on the CITE-Seq method to use barcoded antibody signals as a fingerprint for demultiplexing, allowing for robust sample multiplexing and ‘multiplet’ determination, thereby increasing overall scRNA-Seq data quality.<sup>92</sup> For ultra-high-throughput applications, combinatorial preindexing of entire transcriptomes inside permeabilized cells enables cost-effective scRNA-Seq for millions of individual cells.<sup>78,93</sup> Sample multiplexing, regardless of the method used, can be used to reduce the cost per sample of library preparation, detect doublets and other technical artifacts, and enable sample pooling to mitigate batch effects. Ultimately, highly multiplexed experiments can combine many treatments, analogous to high-content screening approaches.<sup>78</sup>

## VASA-Seq

Conventional scRNA-Seq methods amplify polyadenylated termini of transcripts, failing to capture long noncoding, short noncoding, and nonpolyadenylated protein coding transcripts that may be present in the cellular transcriptome. Vast transcriptome analysis of single cells by dA-tailing, or VASA-Seq, is a scRNA-Seq method that captures the total transcriptome in single cells.<sup>94</sup> Data obtained using VASA-Seq also provides improved alternative splicing detection and RNA velocity analysis.

## Summary

Single-cell transcriptomics is a powerful discovery tool, enabling deeper insight into cellular heterogeneity in complex biological systems. scRNA-Seq can be applied across a breadth of research areas, with the potential to transform our understanding of cellular function in health and disease. Illumina is committed to developing technology solutions to support the evolving landscape of single-cell research. Researchers can leverage Illumina sequencing systems to access highly accurate and sensitive scRNA-Seq data. Flexible NGS readouts are well suited to be used with high-throughput multiomics workflows. Integration with the DRAGEN Single-Cell App simplifies data analysis and generates outputs that are compatible with commercially available single-cell data visualization pipelines.

## Learn more

Single-cell RNA-Seq, [illumina.com/techniques/sequencing/rna-sequencing/ultra-low-input-single-cell-rna-seq](https://illumina.com/techniques/sequencing/rna-sequencing/ultra-low-input-single-cell-rna-seq)

Illumina sequencing systems, [illumina.com/systems/sequencing-platforms](https://illumina.com/systems/sequencing-platforms)

Illumina DRAGEN Bio-IT Platform, [illumina.com/products/by-type/informatics-products/dragen-bio-it-platform](https://illumina.com/products/by-type/informatics-products/dragen-bio-it-platform)

## References

1. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet.* 2009;10:57–63.
2. Wilhelm BT, Landry JR. RNA-Seq—quantitative measurement of expression through massively parallel RNA sequencing. *Methods.* 2009;48:249–57.
3. Aldridge S, Teichmann SA. Single cell transcriptomics comes of age. *Nat Commun.* 2020;11(1):4307. doi:10.1038/s41467-020-18158-5
4. Karlsson M, Zhang C, Méar L, et al. A single-cell type transcriptomics map of human tissues. *Sci Adv.* 2021;7(31):eabh2169. doi:10.1126/sciadv.abh2169
5. Human Cell Atlas. [humancellatlas.org](https://humancellatlas.org). Accessed November 8, 2022.

6. Bilate AM, London M, Castro TBR, et al. T Cell Receptor Is Required for Differentiation, but Not Maintenance, of Intestinal CD4+ Intraepithelial Lymphocytes. *Immunity*. 2020;53(5):1001-1014.e20. doi:10.1016/j.immuni.2020.09.003
7. Lee B, Namkoong H, Yang Y, et al. Single-cell sequencing unveils distinct immune microenvironments with CCR6-CCL20 crosstalk in human chronic pancreatitis. *Gut*. 2022;71(9):1831-1842. doi:10.1136/gutjnl-2021-324546
8. Zhang SQ, Ma KY, Schonnesen AA, et al. High-throughput determination of the antigen specificities of T cell receptors in single cells. *Nat Biotechnol*. Published online November 12, 2018. doi:10.1038/nbt.4282
9. Bentzen AK, Marquard AM, Lyngaa R, et al. Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. *Nat Biotechnol*. 2016;34(10):1037-1045. doi:10.1038/nbt.3662
10. Sheih A, Voillet V, Hanafi LA, et al. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. *Nat Commun*. 2020;11(1):219. doi:10.1038/s41467-019-13880-1
11. Yang HQ, Wang YS, Zhai K, Tong ZH. Single-Cell TCR Sequencing Reveals the Dynamics of T Cell Repertoire Profiling During Pneumocystis Infection. *Front Microbiol*. 2021;12:637500. doi:10.3389/fmicb.2021.637500
12. Sun H, Yang HQ, Zhai K, Tong ZH. Signatures of B Cell Receptor Repertoire Following Pneumocystis Infection. *Front Microbiol*. 2021;12:636250. doi:10.3389/fmicb.2021.636250
13. Setliff I, Shiakolas AR, Pilewski KA, et al. High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. *Cell*. 2019;179(7):1636-1646.e15. doi:10.1016/j.cell.2019.11.003
14. Mathew NR, Jayanthan JK, Smirnov IV, et al. Single-cell BCR and transcriptome analysis after influenza infection reveals spatiotemporal dynamics of antigen-specific B cells. *Cell Rep*. 2021;35(12):109286. doi:10.1016/j.celrep.2021.109286
15. He B, Liu S, Wang Y, et al. Rapid isolation and immune profiling of SARS-CoV-2 specific memory B cell in convalescent COVID-19 patients via LIBRA-seq. *Signal Transduct Target Ther*. 2021;6(1):195. doi:10.1038/s41392-021-00610-7
16. Shiakolas AR, Kramer KJ, Johnson NV, et al. Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking. *Nat Biotechnol*. 2022;40(8):1270-1275. doi:10.1038/s41587-022-01232-2
17. King HW, Wells KL, Shipony Z, et al. Integrated single-cell transcriptomics and epigenomics reveals strong germinal center-associated etiology of autoimmune risk loci. *Sci Immunol*. 2021;6(64):eabh3768. doi:10.1126/sciimmunol.abh3768
18. Smillie CS, Biton M, Ordovas-Montanes J, et al. Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis. *Cell*. 2019;178(3):714-730.e22. doi:10.1016/j.cell.2019.06.029
19. Perez RK, Gordon MG, Subramaniam M, et al. Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus. *Science*. 2022;376(6589):eabf1970. doi:10.1126/science.abf1970
20. Ding J, Adiconis X, Simmons SK, et al. Systematic comparison of single-cell and single-nucleus RNA-sequencing methods. *Nat Biotechnol*. 2020;38(6):737-746. doi:10.1038/s41587-020-0465-8
21. Allen Brain Map. Cell Types Database: RNA-Seq Data. [portal.brain-map.org/atlas-and-data/rnaseq](https://portal.brain-map.org/atlas-and-data/rnaseq). Accessed November 7, 2022.
22. Eze UC, Bhaduri A, Haeussler M, Nowakowski TJ, Kriegstein AR. Single-cell atlas of early human brain development highlights heterogeneity of human neuroepithelial cells and early radial glia. *Nat Neurosci*. 2021;24(4):584-594. doi:10.1038/s41593-020-00794-1
23. Morabito S, Miyoshi E, Michael N, et al. Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer's disease. *Nat Genet*. 2021;53(8):1143-1155. doi:10.1038/s41588-021-00894-z
24. Gate D, Saligrama N, Leventhal O, et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease. *Nature*. 2020;577(7790):399-404. doi:10.1038/s41586-019-1895-7
25. Beltrán E, Gerdes LA, Hansen J, et al. Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis. *J Clin Invest*. 2019;129(11):4758-4768. doi:10.1172/JCI128475
26. Ramesh A, Schubert RD, Greenfield AL, et al. A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. *Proc Natl Acad Sci U S A*. 2020;117(37):22932-22943. doi:10.1073/pnas.2008523117
27. Song E, Bartley CM, Chow RD, et al. Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. *Cell Rep Med*. 2021;2(5):100288. doi:10.1016/j.xcrm.2021.100288
28. Kumar P, Lim A, Hazirah SN, et al. Single-cell transcriptomics and surface epitope detection in human brain epileptic lesions identifies pro-inflammatory signaling. *Nat Neurosci*. 2022;25(7):956-966. doi:10.1038/s41593-022-01095-5
29. Cao J, Spielmann M, Qiu X, et al. The single-cell transcriptional landscape of mammalian organogenesis. *Nature*. 2019;566(7745):496-502. doi:10.1038/s41586-019-0969-x
30. Al Abbar A, Ngai SC, Nograles N, Alhaji SY, Abdullah S. Induced Pluripotent Stem Cells: Reprogramming Platforms and Applications in Cell Replacement Therapy. *BioResearch Open Access*. 2020;9(1):121-136. doi:10.1089/biores.2019.0046
31. Cuomo ASE, Seaton DD, McCarthy DJ, et al. Single-cell RNA-sequencing of differentiating iPS cells reveals dynamic genetic effects on gene expression. *Nat Commun*. 2020;11(1):810.

- doi:10.1038/s41467-020-14457-z
32. Sun C, Wang L, Wang H, et al. Single-cell RNA-seq highlights heterogeneity in human primary Wharton's jelly mesenchymal stem/stromal cells cultured *in vitro*. *Stem Cell Res Ther*. 2020;11(1):149. doi:10.1186/s13287-020-01660-4
  33. Sun C, Wang H, Ma Q, et al. Time-course single-cell RNA sequencing reveals transcriptional dynamics and heterogeneity of limbic stem cells derived from human pluripotent stem cells. *Cell Biosci*. 2021;11(1):24. doi:10.1186/s13578-021-00541-4
  34. Llorens-Bobadilla E, Zhao S, Baser A, Saiz-Castro G, Zwadlo K, Martin-Villalba A. Single-Cell transcriptomics reveals a population of dormant neural stem cells that become activated upon brain injury. *Cell Stem Cell*. 2015;17(3):329-340. doi:10.1016/j.stem.2015.07.002
  35. Wang H, Mei Y, Luo C, et al. Single-cell analyses reveal mechanisms of cancer stem cell maintenance and epithelial-mesenchymal transition in recurrent bladder cancer. *Clin Cancer Res*. 2021;27(22):6265-6278. doi:10.1158/1078-0432.CCR-20-4796
  36. Couturier CP, Ayyadhury S, Le PU, et al. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. *Nat Commun*. 2020;11(1):3406. doi:10.1038/s41467-020-17186-5
  37. Johansson E, Ueno H. Characterization of normal and cancer stem-like cell populations in murine lingual epithelial organoids using single-cell RNA sequencing. *Sci Rep*. 2021;11(1):22329. doi:10.1038/s41598-021-01783-5
  38. Zheng H, Pomyen Y, Hernandez MO, et al. Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. *Hepatology*. 2018;68(1):127-140. doi:10.1002/hep.29778
  39. Han LO, Li XY, Cao MM, Cao Y, Zhou LH. Development and validation of an individualized diagnostic signature in thyroid cancer. *Cancer Med*. 2018;7(4):1135-1140. doi:10.1002/cam4.1397
  40. Zhou JG, Liang B, Jin SH, et al. Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma. *Front Oncol*. 2019;9:1361. doi:10.3389/fonc.2019.01361
  41. Shukla S, Evans JR, Malik R, et al. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. *J Natl Cancer Inst*. 2017;109(1). doi:10.1093/jnci/djw200
  42. Cui Zhou D, Jayasinghe RG, Chen S, et al. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. *Nat Genet*. 2022;54(9):1390-1405. doi:10.1038/s41588-022-01157-1
  43. Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. *Science*. 2014;344(6190):1396-1401. doi:10.1126/science.1254257
  44. Tirosh I, Venteicher AS, Hebert C, et al. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. *Nature*. 2016;539(7628):309-313. doi:10.1038/nature20123
  45. Roerink SF, Sasaki N, Lee-Six H, et al. Intra-tumour diversification in colorectal cancer at the single-cell level. *Nature*. 2018;556(7702):457-462. doi:10.1038/s41586-018-0024-3
  46. Wu F, Fan J, He Y, et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. *Nat Commun*. 2021;12(1):2540. doi:10.1038/s41467-021-22801-0
  47. Puram SV, Tirosh I, Parkhi AS, et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. *Cell*. 2017;171(7):1611-1624.e24. doi:10.1016/j.cell.2017.10.044
  48. Andreatta M, Corria-Osorio J, Müller S, Cubas R, Coukos G, Carmona SJ. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. *Nat Commun*. 2021;12(1):2965. doi:10.1038/s41467-021-23324-4
  49. Zilionis R, Engblom C, Pfirschke C, et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. *Immunity*. 2019;50(5):1317-1334.e10. doi:10.1016/j.immuni.2019.03.009
  50. Guo X, Zhang Y, Zheng L, et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. *Nat Med*. 2018;24(7):978-985. doi:10.1038/s41591-018-0045-3
  51. Krishna S, Lowery FJ, Copeland AR, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. *Science*. 2020;370(6522):1328-1334. doi:10.1126/science.abb9847
  52. Zhang Q, He Y, Luo N, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. *Cell*. 2019;179(4):829-845.e20. doi:10.1016/j.cell.2019.10.003
  53. Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance. *Annu Rev Pathol*. 2021;16:223-249. doi:10.1146/annurev-pathol-042020-042741
  54. Wu TD, Madireddi S, de Almeida PE, et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. *Nature*. 2020;579(7798):274-278. doi:10.1038/s41586-020-2056-8
  55. Fairfax BP, Taylor CA, Watson RA, et al. Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma. *Nat Med*. 2020;26(2):193-199. doi:10.1038/s41591-019-0734-6
  56. Jerby-Arnon L, Shah P, Cuoco MS, et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint

- blockade. *Cell*. 2018;175(4):984-997.e24. doi:10.1016/j.cell.2018.09.006
57. Tirosh I, Izar B, Prakadan SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. *Science*. 2016;352(6282):189-196. doi:10.1126/science.aad0501
58. Nyakas M, Fleten KG, Haugen MH, et al. AXL inhibition improves BRAF-targeted treatment in melanoma. *Sci Rep*. 2022;12(1):5076. doi:10.1038/s41598-022-09078-z
59. Gambardella G, Viscido G, Tumaini B, Isacchi A, Bosotti R, di Bernardo D. A single-cell analysis of breast cancer cell lines to study tumour heterogeneity and drug response. *Nat Commun*. 2022;13(1):1714. doi:10.1038/s41467-022-29358-6
60. Liu T, Zhou L, Li D, Andl T, Zhang Y. Cancer-associated fibroblasts build and secure the tumor microenvironment. *Front Cell Dev Biol*. 2019;7:60. doi:10.3389/fcell.2019.00060
61. Anjanappa M, Cardoso A, Cheng L, et al. Individualized breast cancer characterization through single-cell analysis of tumor and adjacent normal cells. *Cancer Res*. 2017;77(10):2759-2769. doi:10.1158/0008-5472.CAN-16-3308
62. Bartoschek M, Oskolkov N, Bocci M, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. *Nat Commun*. 2018;9(1):5150. doi:10.1038/s41467-018-07582-3
63. Bian S, Hou Y, Zhou X, et al. Single-cell multiomics sequencing and analyses of human colorectal cancer. *Science*. 2018;362(6418):1060-1063. doi:10.1126/science.aao3791
64. Cheng YH, Chen YC, Lin E, et al. Hydro-Seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells. *Nat Commun*. 2019;10(1):2163. doi:10.1038/s41467-019-10122-2
65. Powell AA, Talasz AH, Zhang H, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. *PLoS One*. 2012;7(5):e33788. doi:10.1371/journal.pone.0033788
66. Aceto N, Bardia A, Miyamoto DT, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. *Cell*. 2014;158(5):1110-1122. doi:10.1016/j.cell.2014.07.013
67. Aceto N, Bardia A, Wittner BS, et al. AR Expression in breast cancer CTCs associates with bone metastases. *Mol Cancer Res*. 2018;16(4):720-727. doi:10.1158/1541-7786.MCR-17-0480
68. D'Avola D, Villacorta-Martin C, Martins-Filho SN, et al. High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. *Sci Rep*. 2018;8(1):11570. doi:10.1038/s41598-018-30047-y
69. Miyamoto DT, Zheng Y, Wittner BS, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. *Science*. 2015;349(6254):1351-1356. doi:10.1126/science.aab0917
70. Chen CL, Mahalingam D, Osmulski P, et al. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. *The Prostate*. 2013;73(8):813-826. doi:10.1002/pros.22625
71. Negishi R, Yamakawa H, Kobayashi T, et al. Transcriptomic profiling of single circulating tumor cells provides insight into human metastatic gastric cancer. *Commun Biol*. 2022;5(1):20. doi:10.1038/s42003-021-02937-x
72. Macosko EZ, Basu A, Satija R, et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. *Cell*. 2015;161(5):1202-1214. doi:10.1016/j.cell.2015.05.002
73. Klein AM, Mazutis L, Akartuna I, et al. Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. *Cell*. 2015;161(5):1187-1201. doi:10.1016/j.cell.2015.04.044
74. Zheng GXY, Terry JM, Belgrader P, et al. Massively parallel digital transcriptional profiling of single cells. *Nat Commun*. 2017;8:14049. doi:10.1038/ncomms14049
75. Rettig JR, Folch A. Large-scale single-cell trapping and imaging using microwell arrays. *Anal Chem*. 2005;77(17):5628-5634. doi:10.1021/ac0505977
76. Han X, Wang R, Zhou Y, et al. Mapping the Mouse Cell Atlas by Microwell-Seq. *Cell*. 2018;172(5):1091-1107.e17. doi:10.1016/j.cell.2018.02.001
77. Cao C, Lemaire LA, Wang W, et al. Comprehensive single-cell transcriptome lineages of a proto-vertebrate. *Nature*. 2019;571(7765):349-354. doi:10.1038/s41586-019-1385-y
78. Srivatsan SR, McFaline-Figueroa JL, Ramani V, et al. Massively multiplex chemical transcriptomics at single-cell resolution. *Science*. 2020;367(6473):45-51. doi:10.1126/science.aax6234
79. Stoeckius M, Hafemeister C, Stephenson W, et al. Simultaneous epitope and transcriptome measurement in single cells. *Nat Methods*. 2017;14(9):865-868. doi:10.1038/nmeth.4380
80. Mimitou EP, Cheng A, Montalbano A, et al. Multiplexed detection of proteins, transcriptomes, clonotypes and CRISPR perturbations in single cells. *Nat Methods*. 2019;16(5):409-412. doi:10.1038/s41592-019-0392-0
81. Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-Wide. *Curr Protoc Mol Biol*. 2015;109:21.29.1-21.29.9. doi:10.1002/0471142727.mb2129s109
82. Muto Y, Wilson PC, Ledru N, et al. Single cell transcriptional and chromatin accessibility profiling redefine cellular heterogeneity in the adult human kidney. *Nat Commun*. 2021;12(1):2190. doi:10.1038/s41467-021-22368-w
83. Longo SK, Guo MG, Ji AL, Khavari PA. Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics. *Nat Rev Genet*. 2021;22(10):627-644. doi:10.1038/s41576-021-00370-8

84. Baccin C, Al-Sabah J, Velten L, et al. Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone marrow niche organization. *Nat Cell Biol.* 2020;22(1):38-48. doi:10.1038/s41556-019-0439-6
85. Andersson A, Larsson L, Stenbeck L, et al. Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions. *Nat Commun.* 2021;12(1):6012. doi:10.1038/s41467-021-26271-2
86. Pelka K, Hofree M, Chen JH, et al. Spatially organized multicellular immune hubs in human colorectal cancer. *Cell.* 2021;184(18):4734-4752.e20. doi:10.1016/j.cell.2021.08.003
87. Moncada R, Barkley D, Wagner F, et al. Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas. *Nat Biotechnol.* 2020;38(3):333-342. doi:10.1038/s41587-019-0392-8
88. La Manno G, Soldatov R, Zeisel A, et al. RNA velocity of single cells. *Nature.* 2018;560(7719):494-498. doi:10.1038/s41586-018-0414-6
89. Ranek JS, Stanley N, Purvis JE. Integrating temporal single-cell gene expression modalities for trajectory inference and disease prediction. *Genome Biol.* 2022;23(1):186. doi:10.1186/s13059-022-02749-0
90. McGinnis CS, Patterson DM, Winkler J, et al. MULTI-seq: sample multiplexing for single-cell RNA sequencing using lipid-tagged indices. *Nat Methods.* 2019;16(7):619-626. doi:10.1038/s41592-019-0433-8
91. Kang HM, Subramaniam M, Targ S, et al. Multiplexed droplet single-cell RNA-sequencing using natural genetic variation. *Nat Biotechnol.* 2018;36(1):89-94. doi:10.1038/nbt.4042
92. Stoeckius M, Zheng S, Houck-Loomis B, et al. Cell Hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics. *Genome Biol.* 2018;19(1):224. doi:10.1186/s13059-018-1603-1
93. Datlinger P, Rendeiro AF, Boenke T, et al. Ultra-high-throughput single-cell RNA sequencing and perturbation screening with combinatorial fluidic indexing. *Nat Methods.* 2021;18(6):635-642. doi:10.1038/s41592-021-01153-z
94. Salmen F, De Jonghe J, Kaminski TS, et al. High-throughput total RNA sequencing in single cells using VASA-seq. *Nat Biotechnol.* Published online June 27, 2022. doi:10.1038/s41587-022-01361-8



1.800.809.4566 toll-free (US) | +1.858.202.4566 tel  
techsupport@illumina.com | www.illumina.com

© 2022 Illumina, Inc. All rights reserved. All trademarks are the property of Illumina, Inc. or their respective owners. For specific trademark information, see [www.illumina.com/company/legal.html](http://www.illumina.com/company/legal.html).  
M-GL-01139 v1.0